Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Tuesday.
Separately, Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Friday, March 17th.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) remained flat at $1.38 during mid-day trading on Tuesday. The company’s stock had a trading volume of 228,652 shares. The company’s market cap is $30.94 million. The stock has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.28. Marinus Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $2.73.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Monday, May 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.06. Equities research analysts expect that Marinus Pharmaceuticals will post ($1.00) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2656253/marinus-pharmaceuticals-inc-mrns-upgraded-by-valuengine-to-sell.html.
Several institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. boosted its position in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 14,692 shares in the last quarter. Jennison Associates LLC purchased a new position in Marinus Pharmaceuticals during the first quarter valued at about $690,000. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals by 249.9% in the first quarter. Vanguard Group Inc. now owns 653,651 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 466,830 shares in the last quarter. Granite Point Capital Management L.P. purchased a new position in Marinus Pharmaceuticals during the first quarter valued at about $1,372,000. Finally, Nexthera Capital LP purchased a new position in Marinus Pharmaceuticals during the first quarter valued at about $1,416,000. Hedge funds and other institutional investors own 32.69% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.